All In Biotech

BLA 125460 · Biomarin Pharm

Vimizim

Elosulfase Alfa · Injection · Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Feb 14, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

5

2 Phase 3, 1 recruiting

FAERS reports

5,517

2,246 serious, 134 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS and RISK OF ACUTE RESPIRATORY COMPLICATIONS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VIMIZIM and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . Patients...

What it is approved for

From the label in effect Oct 30, 2025.

VIMIZIM (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). VIMIZIM is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). ( 1 )

Mechanism: Mucopolysaccharidoses comprise a group of lysosomal storage disorders caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome) is characterized by the absence or marked reduction in N -acetylgalactosamine-6-sulfatase activity. The sulfatase activity deficiency results in the accumulation of the GAG substrates, KS and C6S, in the lysosomal compartment of cells throughout the body. The accumulation leads to widespread cellular, tissue, and organ dysfunction. VIMIZIM is intended to...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VIMIZIM · ELOSULFASE ALFA 5MG/5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Elosulfase Alfa" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia742
  • cough353
  • vomiting333
  • malaise287
  • headache261
  • pain241
  • dyspnoea238
  • nausea228
  • fatigue202
  • nasopharyngitis199
  • pneumonia172
  • oxygen saturation decreased155

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2014151
2015436
2016526
2017445
2018440
2019470
2020406
2021475
2022465
2023467
2024425
2025460
2026351

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vimizim (Elosulfase Alfa)

2024 spending

$15.5M

Beneficiaries

16

156 claims

Per beneficiary

$965,713

$286.19 per unit

View as table
YearSpending
2020$13,459,121
2021$13,731,158
2022$13,803,740
2023$16,893,194
2024$15,451,405

Part B: Vimizim (Elosulfase Alfa) · HCPCS J1322

2024 spending

$2.6M

Beneficiaries

n/a

110 claims

Per beneficiary

n/a

2024 ASP limit $286.65 per unit

View as table
YearSpending
2020$2,415,712
2021$2,197,743
2022$2,027,234
2023$2,169,684
2024$2,569,194

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 16 on PubMed

Sponsor: BioMarin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.